Acción IMNN IMUNON, INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Imunon, Inc.

Acciones

IMNN

US15117N6022

Diferido Nasdaq
Otros sitios de cotización
 19:13:46 30/04/2024 		Varia. Cinco días. Varia. 1 de enero.
1,303 USD -3,79 % Gráfico intradía de Imunon, Inc. -2,00 % +91,68 %
18/04 Imunon, Inc. Solicitud autorizada para comenzar las pruebas en humanos de IMNN-101 CI
01/04 IMUNON, INC. : Obtiene una recomendación de compra de HC Wainwright ZM

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Imunon Receives FDA Approval to Start Phase 1 Trial of COVID-19 Booster Vaccine
Imunon Shares Rise 8% After Clearance to Start Phase 1 Trial for Covid-19 Booster Vaccine
IMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101
Imunon, Inc. Application Cleared to Begin Human Testing of IMNN-101
IMUNON Reports Compliance with Nasdaq Listing Requirements
Top Midday Gainers
Imunon, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
IMUNON Reports 2023 Financial Results and Provides Business Update
North American Morning Briefing : Stocks Set for -2-
IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses
IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024
IMUNON Files IND Application to Begin Human Testing of IMNN-101
Imunon, Inc. Files Ind Application to Begin Human Testing of Imnn-101
IMUNON Names Executive Chairman as Temporary Head Following Resignation of CEO Corinne Le Goff
IMUNON Announces Leadership Change
Imunon, Inc. Announces Executive Changes
Imunon, Inc. Announces Resignation of Corinne Le Goff as Chief Executive Officer, Effective March 15, 2024
Independent Lab Confirms Immunogenicity and Protection with IMUNON’s IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5
Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer
IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción IMNN
  4. Noticias Imunon, Inc.
  5. Otros idiomas